PE20060768A1 - PHARMACEUTICAL COMPOSITION INCLUDING HYDROCHLOROTHIAZIDE AND TELMISARTANE - Google Patents

PHARMACEUTICAL COMPOSITION INCLUDING HYDROCHLOROTHIAZIDE AND TELMISARTANE

Info

Publication number
PE20060768A1
PE20060768A1 PE2005001465A PE2005001465A PE20060768A1 PE 20060768 A1 PE20060768 A1 PE 20060768A1 PE 2005001465 A PE2005001465 A PE 2005001465A PE 2005001465 A PE2005001465 A PE 2005001465A PE 20060768 A1 PE20060768 A1 PE 20060768A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
hydrochlorothiazide
composition including
telmisartane
composition
Prior art date
Application number
PE2005001465A
Other languages
Spanish (es)
Inventor
Helmut E Schumacher
Axel Riedel
Peter Bohm
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35589356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060768(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20060768A1 publication Critical patent/PE20060768A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE 80 MG DE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA II TAL COMO EL TELMISARTANO Y 25 MG DE UN DIURETICO TAL COMO HIDROCLOROTIAZIDA. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA QUE PUEDE DIVIDIRSE EN MITADES QUE COMPRENDE 160 MG DE TELMISARTANO Y 50 MG DE HIDROCLOROTIAZIDA. LA COMPOSICION PUEDE CONTENER, ADEMAS, HIDROXIDO DE SODIO, MEGLUMINA, POVIDONA, SORBITOL, ESTEARATO DE MAGNESIO, LACTOSA MONOHIDRATADA, CELULOSA MICROCRISTALINA, ALMIDON DE MAIZ, ENTRE OTROS. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE LA HIPERTENSION, ACCIDENTES CEREBRO VASCULARES, INSUFICIENCIA CARDIACA CONGESTIVA, RESISTENCIA A LA INSULINA, ENTRE OTROSREFERRING TO A PHARMACEUTICAL COMPOSITION INCLUDING 80 MG OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST SUCH AS TELMISARTAN AND 25 MG OF A DIURETIC SUCH AS HYDROCHLOROTHIAZIDE. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION THAT CAN BE DIVIDED INTO HALVES, INCLUDING 160 MG OF TELMISARTAN AND 50 MG OF HYDROCHLOROTHIAZIDE. THE COMPOSITION MAY ALSO CONTAIN SODIUM HYDROXIDE, MEGLUMIN, POVIDONE, SORBITOL, MAGNESIUM STEARATE, MONOHYDRATED LACTOSE, MICROCRYSTALLINE CELLULOSE, CORN STARCH, AMONG OTHERS. SUCH COMPOSITION IS USEFUL FOR THE TREATMENT OF HYPERTENSION, VASCULAR BRAIN ACCIDENTS, CONGESTIVE HEART FAILURE, INSULIN RESISTANCE, AMONG OTHERS

PE2005001465A 2004-12-17 2005-12-15 PHARMACEUTICAL COMPOSITION INCLUDING HYDROCHLOROTHIAZIDE AND TELMISARTANE PE20060768A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63706204P 2004-12-17 2004-12-17

Publications (1)

Publication Number Publication Date
PE20060768A1 true PE20060768A1 (en) 2006-09-29

Family

ID=35589356

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001465A PE20060768A1 (en) 2004-12-17 2005-12-15 PHARMACEUTICAL COMPOSITION INCLUDING HYDROCHLOROTHIAZIDE AND TELMISARTANE

Country Status (15)

Country Link
EP (1) EP1827424A1 (en)
JP (1) JP2008524136A (en)
KR (1) KR20070097511A (en)
CN (1) CN101080225A (en)
AR (1) AR052052A1 (en)
AU (1) AU2005315855A1 (en)
BR (1) BRPI0519656A2 (en)
CA (1) CA2589493A1 (en)
EA (1) EA200701159A1 (en)
IL (1) IL183944A0 (en)
NO (1) NO20072325L (en)
PE (1) PE20060768A1 (en)
TW (1) TW200637546A (en)
UY (1) UY29274A1 (en)
WO (1) WO2006063737A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8637078B2 (en) * 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
SI2180882T1 (en) * 2007-10-19 2013-05-31 Otsuka Pharmaceutical Co., Ltd. Solid matrix pharmaceutical preparation
EP2203158A4 (en) 2007-10-30 2012-12-26 Reddys Lab Ltd Dr Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
US20110008428A1 (en) 2008-03-19 2011-01-13 Ratiopharm Gmbh Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic
CN102164918B (en) * 2008-07-31 2014-05-07 武田药品工业株式会社 Solid pharmaceutical composition
GB0822170D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Telmisartan with diuretic formulations
EP2443094B1 (en) 2009-06-19 2013-03-20 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
EP2448576A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2448575A2 (en) * 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
TR200906506A2 (en) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Solid dosage forms containing telmisartan.
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
WO2014119767A1 (en) * 2013-01-31 2014-08-07 沢井製薬株式会社 Multilayer tablet containing telmisartan and hydrochlorothiazide
ES2847904T3 (en) * 2013-07-23 2021-08-04 Daiichi Sankyo Co Ltd Medicine for the prevention or treatment of hypertension
CN106562973A (en) * 2016-11-06 2017-04-19 成都先先先生物科技有限公司 Anti-hypertension medicine compound preparation
CN107501192A (en) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 The eutectic of Telmisartan and Hydrochioro
CN108653227A (en) * 2018-08-09 2018-10-16 湖北舒邦药业有限公司 A kind of Telmisartan hydrochlorothiazide tablets and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229085C2 (en) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Elongated, divisible tablet
EP1854454B1 (en) * 2002-01-16 2013-11-06 Boehringer Ingelheim Pharma GmbH & Co. KG Method for the preparation of amorphous telmisartan

Also Published As

Publication number Publication date
TW200637546A (en) 2006-11-01
AU2005315855A1 (en) 2006-06-22
WO2006063737A1 (en) 2006-06-22
NO20072325L (en) 2007-07-06
KR20070097511A (en) 2007-10-04
CN101080225A (en) 2007-11-28
BRPI0519656A2 (en) 2009-03-03
JP2008524136A (en) 2008-07-10
EP1827424A1 (en) 2007-09-05
UY29274A1 (en) 2006-07-31
AR052052A1 (en) 2007-02-28
IL183944A0 (en) 2007-10-31
EA200701159A1 (en) 2007-12-28
CA2589493A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
PE20060768A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING HYDROCHLOROTHIAZIDE AND TELMISARTANE
CL2008003595A1 (en) Nitrogen heterocyclic compounds, tachykinin receptor antagonists; pharmaceutical agent comprising the compound; and use in the prophylaxis or treatment of a lower urinary tract disease, a gastrointestinal disease, or a disease of the central nervous system.
UA86831C2 (en) Extended release tablet formulation comprising pramipexole or pharmaceutically acceptable salt thereof, method for its manufacturing and administration
BRPI0507887A (en) multilayer tablet
AR087210A2 (en) PHARMACEUTICAL FORMULATION OF THE SODIUM SALT OF TELMISARTAN
WO2011014587A3 (en) Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
ECSP10010160A (en) DOUBLE ACTION PHARMACEUTICAL COMPOSITIONS BASED ON ANTAGONIST SUPER-STRUCTURES / ANGIOTENSIN RECEPTOR BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR
ATE380547T1 (en) DOUBLE-LAYER PHARMACEUTICAL TABLET CONTAINING TELMISARTAN AND HYDROCHLOROTHIAZIDE
PE20020082A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING AN ALDOSTERONE-SYNTHASE INHIBITOR AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST (AT1)
CL2008001946A1 (en) Imidazole-derived compounds, ccr2, ccr3, ccr5 receptor antagonists; preparation procedure; and use in the treatment of peripheral vascular diseases.
MY145089A (en) Pharmaceutical composition
DK1719503T3 (en) Use of Starch with Cleaved Side Chains in Extrusion / Spheronization of Pharmaceutical Pellets
EA201001312A1 (en) SOLID PHARMACEUTICAL COMPOSITION CONTAINING NEPEPTIDE ANTAGONIST OF ANGIOTENSIN II RECEPTOR AND DIURETIC
AR066168A1 (en) GALENIC FORMULATIONS OF ORGANIC COMPOUNDS
UY30461A1 (en) PHARMACEUTICAL COMPOSITION FOR ANTI-CONCEPTION AND TO REDUCE THE RISK OF CONGENITAL MALFORMATIONS.
DOP2006000280A (en) NEW SUBSTITUTED ACYCLIC FUROPIRIMIDINE DERIVATIVES AND THEIR USE
EP2540294A4 (en) Sustained-release solid preparation for oral use
PE20120421A1 (en) PHARMACEUTICAL COMPOSITION WHICH INCLUDES HAPPINESS
CL2008001162A1 (en) Compounds derived from piperidine, tachykinin receptor antagonist; pharmaceutical composition comprising said compounds; and use of the compound for the treatment of a lower urinary tract disease, a gastrointestinal disease, a disease of the central nervous system.
PE20020617A1 (en) COMPOSITION INCLUDING AN AT1 RECEPTOR ANTAGONIST AND AN INSULIN SECRETION POTENTIAL OR AN INSULIN SENSITIZER
SI1994926T1 (en) Valsartan formulations
CL2009000896A1 (en) Substituted 3-phenylpyrazolo [5,1-b] thiazole derivative compounds; pharmaceutical composition; Useful in the treatment of depression, anxiety, ischemia, stroke, hypertension, schizophrenia, among other diseases.
AR048970A1 (en) SOLID PHARMACEUTICAL FORMULATION
CR11766A (en) IMINOPIRIDINE DERIVATIVES AND USE OF THE SAME
PE20090675A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING LEVOSIMENDAN AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST OR AN ACE INHIBITOR

Legal Events

Date Code Title Description
FC Refusal